BioCentury
ARTICLE | Clinical News

IV CR845: Completed Phase II enrollment

June 29, 2015 7:00 AM UTC

Cara completed enrollment of 65 hemodialysis patients with uremic pruritus in a double-blind, placebo-controlled, U.S. Phase II trial evaluating 0.5, 1 and 2.5 ug/kg IV CR845 thrice weekly for 1 week ...